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Nitric Oxide (NO) is a small molecule that continues to attract much attention from the
scientific community. Since its discovery, it has been evident that NO has a crucial role in
the modulation of vascular tone. Moreover, NO is involved in multiple signal transduction
pathways thus contributing to the regulation of many cellular functions. NO effects can
be either dependent or independent on cGMP, and rely also upon several mechanisms
such as the amount of NO, the compartmentalization of the enzymes responsible for
its biosynthesis (NOS), and the local redox conditions. Several evidences highlighted the
correlation among adrenoreceptors activity, vascular redox status and NO bioavailability.
It was suggested a possible crosstalk between NO and oxidative stress hallmarks in
the endothelium function and adaptation, and in sympathetic vasoconstriction control.
Adrenergic vasoconstriction is a balance between a direct vasoconstrictive effect on
smooth muscle and an indirect vasorelaxant action caused by α2- and β-adrenergic
endothelial receptor-triggered NO release. An increased oxidative stress and a reduction
of NO bioavailability shifts this equilibrium causing the enhanced vascular adrenergic
responsiveness observed in hypertension. The activity of NOS contributes to manage
the adrenergic pathway, thus supporting the idea that the endothelium might control or
facilitate β-adrenergic effects on the vessels and the polymorphic variants in β2-receptors
and NOS isoforms could influence aging, some pathological conditions and individual
responses to drugs. This seems to be dependent, almost in part, on differences in
the control of vascular tone exerted by NO. Given its involvement in such important
mechanisms, the NO pathway is implicated in aging process and in both cardiovascular
and non-cardiovascular conditions. Thus, it is essential to pinpoint NO involvement in
the regulation of vascular tone for the effective clinical/therapeutic management of
cardiovascular diseases (CVD).
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INTRODUCTION
Nitric Oxide (NO) is a small gaseous molecule recognized as a
ubiquitous intercellular messenger modulating crucial functions
including blood flow, platelet aggregation, and neural activity
(Moncada, 1994).
This molecule is synthesized from L-arginine by three iso-
forms of Nitric Oxide Synthases (NOSs) and all of them (nNOS,
Inos, and eNOS) concur to regulate the autonomic nervous
system.
NO exerts its activity essentially by stimulating soluble
Guanylyl Cyclase (GC) to increase the levels of the second mes-
senger cGMP, which in turn modulates the performance of
adrenergic receptors (ARs).
Recently, many studies highlighted an important role in the
regulation of the vasomotor tone of the β-adrenoreceptor subtype
β3, which, differently from the classical β1- and β2-ARs, induces a
negative inotropism in the human heart (Balligand, 1999; Salazar
et al., 2013).
NO effects depend, among others, on NO concentration, com-
partmentalization of NOS enzymes and local redox conditions of
cells and tissues and, to date, many evidences collected by both
in vivo and in vitro experiments suggest a crosstalk between NO,
ARs and oxidative stress in the control of endothelium homeosta-
sis, and in the sympathetic regulation of the vascular tone (Graves
and Poston, 1993; Lembo et al., 2000; Selemidis et al., 2007).
The NO pathway is directly implicated in the development
and progression of diseases such as hypertension and heart failure
(HF) and, recently, this molecule has been considered a promis-
ing target to develop new clinical strategies against cardiovascular
pathologies (Levy et al., 2009).
In addition, it is worth noting that some studies showed that
polymorphisms in genes encoding for ARs and NOS enzymes
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could influence aging, onset and progression of cardiovascular
diseases (CVD), and response to therapy (Jáchymová et al., 2001;
Garovic et al., 2003).
The main focus of this review is the mechanisms underlying
the interconnection between β-ARs and NO in the cardiovascular
system, and the therapeutic potential of new discoveries in this
field.
NO MODULATES VASOMOTOR TONE BY INTERFERING WITH
SYMPATHETIC AUTONOMIC NERVOUS SYSTEM
In 1980s the Endothelium-Derived Relaxing Factor (EDRF), dis-
covered by Moncada, was identified as NO (Hutchinson et al.,
1987; Palmer et al., 1987) and, from that moment, several stud-
ies shed light on a countless number of important roles played by
this molecule which was proclaimed Science’s “Molecule of the
Year 1992” (Nathan, 1992, 1995; Bredt and Snyder, 1994).
Since its discovery, it was clear that NO acts as a key mod-
ulator of the vascular tone and that its vascular effects are
generally mediated by Guanosine 3′,5′-cyclic MonoPhosphate
(cGMP) through the activation of guanylate cyclase. In fact,
several experiments using NO donors and/or cGMP analogs
have shown that cGMP is a critical and multifunctional sec-
ond messenger that mediates several functions in cardiac and
vascular tissues as well as the etiology and pathophysiology
of cardiovascular disorders (Tulis, 2008). Both neurotransmit-
ters and hormones released from autonomic nervous system
cooperate to preserve the balance between vasoconstriction and
vasorelaxation and to control cardiac muscle cells function, and
it is now generally accepted that NO exerts a critical role in
this context. Balligand et al., which investigated the effects of
NOS inhibitors in isolated neonatal and adult rat ventricular
myocytes, exposed to either muscarinic or adrenergic agonists,
concluded that the physiological response of the cells to both
muscarinic cholinergic and β-adrenergic stimulation is medi-
ated, at least in part, by NO production (Balligand et al.,
1993).
Cardiovascular homeostasis is regulated by NO produced by
all three NOS isoforms. Several studies demonstrated, both in vivo
(Schwarz et al., 1995) and in vitro (Horackova et al., 1995), that
NO produced by neuronal NOS (nNOS) controls catecholamines
release in response to electrical adrenergic nerve stimulation. This
is very important also in consideration that elevated levels of
cathecolamines are associated to several pathologic conditions
such as HF (Rengo et al., 2012a).
The inducible NO Synthase (iNOS) has been also involved
in several aspects of cardiovascular biology such as the defence
against intracellular microorganisms (Balligand and Cannon,
1997).
Moreover, endothelial cells express, in heart and vessels of a
variety of species including humans, endothelial NO Synthase
(eNOS), an isoform that is activated to produce NO in response
to stimulation of both adrenergic and muscarinic cholinergic
receptors in cardiac myocytes (Balligand et al., 1995).
Many studies demonstrated that vascular endothelial cells
might also express β-adrenoceptors (Buxton et al., 1987;
Molenaar et al., 1988), thus supporting the idea that the endothe-
liummight control or facilitate β-adrenergic effects on the vessels.
The main mechanism leading to increased eNOS activity in
endothelial cells is calcium-dependent (Wu, 2002), but phospho-
rylation at several loci of the NOS proteins has been recognized
as an additional pathway to induce both activation and inhibition
of eNOS activity (Bauer et al., 2003; Fleming and Busse, 2003).
Both in vivo and in vitro studies suggested that the vascular
endothelium might mediate β-adrenergic vasorelaxation, though
not all the results presented are in agreement with each other. For
instance, it was observed that rat mesenteric resistance arteries
can be relaxed by NO release upon β1-adrenoreceptor stimulation
(Graves and Poston, 1993). Priest et al. showed an involvement
of NO in β-mediated vasorelaxation in large but not in small rat
arteries suggesting a role of NO strictly dependent on the vascular
area (Priest et al., 1997).
Ferro et al. verified that the stimulation of β2-adrenoreceptors
led to an increase in NO, which in turn caused relaxation
of Human Umbilical Vein Endothelial Cells (HUVEC). In this
study, the authors provided also a comparison between β-
adrenoreceptor function measured in HUVEC and the response
to β-adrenergic stimuli in intact vessels, showing the impor-
tance of endothelium in maintaining vascular homeostasis
(Ferro et al., 1999). In addition, Lembo et al. suggested
the existence of an endothelium NO component essential
for the insulin modulation of α2- and β-adrenergic vascu-
lar responses. An impairment of the equilibrium between
endothelial and vascular smooth muscle adrenergic signaling
could contribute to the increase of vascular resistance, a piv-
otal phenotypical trait of essential hypertension (Lembo et al.,
1997).
ROLE OF β3-ADRENOCEPTOR
Emerging evidences highlighted a role played by a third β-
adrenoreceptor subtype (β3), traditionally known as a modulator
of lipolysis in adipose tissue, as a regulator of the vasomotor tone
in conjunction with β1- and β2-ARs (Trochu et al., 1999).
The involvement of a β-receptor, other than classical β1- and
β2-ARs, has been suggested in several experiments which used
a different concentration of non-selective β-blockers (Clark and
Bertholet, 1983; Doggrell, 1990; Oriowo, 1995) and preferential
β3-AR agonists (Berlan et al., 1995).
It is now widely accepted that the vasoactive effects depen-
dent on the stimulation of β-ARs are strongly associated with NO
production and activation (Trochu et al., 1999).
Recently, many investigations focused on β3-ARs, which are
detected in human endothelial cells and cardiac myocytes of the
human heart. These receptors subtypes are highly expressed in
the atrium and, in contrast to β1- and β2-ARs, are responsi-
ble of a negative cardiac inotropic effect (Moniotte et al., 2001).
Moreover, on the basis of differential expression of β3-ARs in the
human myocardium chambers, Brixius et al. found that eNOS
is activated by β3-AR predominantly via phosphorylation in the
left ventricle and through a translocation process in the atrium
(Brixius et al., 2004).
The link between β3 AR, eNOS and vasodilation mech-
anism was demonstrated also in in vivo models; recent
advances in the field were achieved by using nebivolol, a
β1-blocker. Dessy et al. verified that nebivolol dilates human
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and rodent coronary resistance microarteries, and showed that
this effect is sensitive to NOS inhibition and is hampered
in β3-adrenoreceptor-deficient mice. Moreover, the authors
showed proangiogenic properties of nebivolol, which are depen-
dent by both eNOS and β3-adrenoreceptors (Dessy et al.,
2005).
Interestingly, β3-AR is upregulated during cardiomyophaties
in humans and this characteristic, together with its peculiar dif-
ferential expression in the human myocardium, makes it an
attractive target for the development of new clinical strategies
against CVD (Moniotte et al., 2001).
Many studies investigated the involvement of β3-AR in the
onset and progression of cardiovascular clinical conditions both
in animal and human models, and it seems conceivable that the
stimulation of β3-AR leads to NO-mediated protective effects
in vascular beds (Dessy et al., 2004, 2005). In addition, in case
of neurohormonal stress, β3-ARs expressed in the endothelium
promote coronary perfusion through their vasodilator and pro-
angiogenic effects (Balligand, 2009).
Recently, a randomized trial, named SENIORS (Study
of the Effects of Nebivolol Intervention on Outcomes and
Rehospitalization in Seniors with HF) was performed to inves-
tigate the effects of nebivolol on the ejection fraction in aged
patients (≥70 years).
Notably, nebivolol possesses vasodilator ancillary properties,
probably mediated by the endothelial L-arginine NO pathway. In
particular, it was demonstrated that the favorable hemodynamic
profile of nebivolol, including the lowering of blood pressure, is
partially due to NO release from endothelial cells (Maffei et al.,
2006). In addition, thanks to its antioxidant activity, nebivolol
prevents the detrimental effect on NO bioavailability associated
to oxidative stress (Ignarro, 2004).
To date, preclinical and clinical data confirm that NO benefits
might due to β3-ARs overexpression. However, caution should be
used, as the long term effects of β3-ARs agonists on left ventricular
function in the heart have not yet been fully evaluated.
Furthermore, many studies investigated the impact of life-
style changes and non-pharmacological interventions on the
cardiovascular homeostasis, and convincing evidences showed a
favorable role exerted by diet and caloric restriction. For exam-
ple, Nisoli et al. demonstrated that caloric restriction leads to
enhanced mitochondrial biogenesis, at least in part, by inducing
the activation of eNOS (Nisoli et al., 2005), and Cerqueira et al.
observed a time-dependent increase of eNOS activation and NO
bioavailability in vascular cells conditioned with serum of caloric
restricted rats (Cerqueira et al., 2012).
Also exercise training (ET), currently used in cardiac rehabil-
itation (CR) programs, was recognized to improve some cardio-
vascular outcomes by inducing NO levels to increase, even if this
strongly depends on both the type and intensity of exercise (Conti
et al., 2012a, 2013).
Jenkins et al. suggested that a regular physical activity in
combination with dietary restriction positively influences, in
a NO-dependent manner, the expression of β-AR and natri-
uretic peptide receptors in adipose tissues of obese rats (Jenkins
et al., 2013). In addition, Calvert et al. showed that an
ET-dependent stimulation of β3-ARs is useful to counteract
myocardial ischemia-reperfusion injury by increasing NO signal-
ing (Calvert et al., 2011).
These and many other studies remarked a crucial role played
by NO in cardiovascular homeostasis.
ADRENORECEPTORS STIMULATION, VASCULAR REDOX
STATE AND NITRIC OXIDE BIOAVAILABILITY
Experimental in vivo and in vitro evidences suggest a crosstalk
between NO, adrenoreceptors and oxidative stress in the function
and adaptation of endothelium, and in the sympathetic control of
the vascular tone.
Excess of ROS and/or failure of antioxidant endogenous
defense may result in ROS-mediated reduction of NO bioavail-
ability in the cells. The influence of oxidative stress on the pathway
of NO biosynthesis has been extensively investigated and its
effects, due to either direct quenching or impaired synthesis of
NO, strongly affect the vasodilation mechanism (Förstermann
and Sessa, 2012).
It has been showed that β2-ARs excitation increases cellu-
lar uptake of L-arginine, an eNOS substrate, and eNOS activity
can be specifically stimulated by these AR subtypes in human
endothelial cells. Moreover, β2-ARs stimulation hyperpolarizes
cellular membrane, and L-NAME, a well known NOS inhibitor,
may hinder this process (Wyatt et al., 2002; Queen et al., 2006).
In vitro experiments using endothelial cells showed an increase
of β2-ARs-mediated eNOS phosphorylation at serine-1177, high-
lighting a β2-AR-dependent NOS activation through a Ca2+
insensitive mechanism (Dimmeler et al., 1999; Queen et al., 2006;
Cannavo et al., 2013a,b).
Recently, Davel et al. investigated the role of oxidative stress
in sympathetic-dependent contractility of human endothelium.
The authors observed an increase of contractile response in β2-
knockout (KO) mice and showed that the loss of function of these
receptors in vascular tissue can induce ROS-mediated NO impair-
ment. Administration of α1-agonist phenylephrine in the aorta
of β2-KO mice suggested a key role played by NO in the control
of vasomotor tone. In fact, the reduction of basal content of NO
enhanced the vasoconstriction rate in the aorta of mice deficient
for β2-adrenoreceptors. These experiments suggested that β2-ARs
in vascular tissues are necessary to maintain basal levels of NO,
thus concurring to modulate vascular homeostasis (Davel et al.,
2012). The lack of functional β2-receptors led to an increase of
oxidative stress in the aorta of β2-KO mice, and a treatment with
antioxidant superoxide dismutase was sufficient to limit the vaso-
constrictor response to phenylephrine. These results suggest the
existence of an important link between adrenergic pathway, NO
bioavailability and oxidative stress.
Indeed, several studies have showed antioxidant properties of
NO, confirming the role of this molecule to counteract superox-
ide anions production by NADPH oxidase, the major source of
superoxide in blood vessels. Several stimuli, such as oscillatory
shear stress, hyperglycemia and lipid peroxidation could cause
impairment in the NADPH oxidase system that, in turn, produces
accumulation of ROS and reduction of NO content (Vecchione
et al., 2006).
Selemidis et al. showed that prolonged exposure of human
endothelial cells to NO donors, such as long-acting nitrates,
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induced a significant decrease of ROS via inhibition of p47phox
NADPH oxidase subunit (Selemidis et al., 2007). By reducing the
oxidative stress, NO donors may exert several vascular protec-
tive effects and they could be used not only for a symptomatic
treatment, but also to prevent and eventually revert many aspects
of CVD.
NO antioxidant properties and the ability of NO donors to
counteract NADPH oxidase-dependent superoxide production
are well established. However, ROS other than superoxide anions
could play a role in determining redox state imbalance and the
resulting detrimental effects on NO biosynthesis. Indeed, car-
diovascular side effects of drugs, such as acetylsalicylic acid and
other ciclooxygenase inhibitors may be due to their influence on
oxidative stress hallmarks in coronary circulation, and coronary
perfusion. In this context, it was suggested that those effects can
be modulated by inhibition of NOS following the increase of
superoxide, hydrogen peroxide and lipid peroxidation (Barudzic
et al., 2013).
Further studies in the field of the antioxidant effect of
adrenergic-dependent NO modulation could be essential to
develop new drugs and clinical strategies to modulate oxidative
stress in vascular diseases.
NITRIC OXIDE AND CARDIOVASCULAR DISEASES
Given its crucial role in the autonomic nervous system con-
trol, the NO pathway is directly implicated in diseases, such as
hypertension and HF.
The generation of NO in the vascular endothelium ensures
the maintenance of the vasodilator tone that is required for the
regulation of blood flow and pressure.
Moreover, NO bioavailability plays an important role in the
pathophysiology of CVD and its reduction in endothelial cells
is strictly associated to endothelial dysfunction and hypertension
(Lyons, 1997; Yetik-Anacak and Catravas, 2006).
The link between endothelial dysfunction and vascular dis-
eases is well established (Rengo et al., 2013a). It is known,
for instance, that impairment of endothelial function precedes
atherosclerosis (Brush et al., 1992).
Stimulation of endothelial β-adrenoreceptors improves eNOS-
derived NO production. The importance of such strong
molecular interconnection has been recently demonstrated in
several studies on nebivolol conducted in animals and in humans.
Nebivolol is a third generation β-blocker used in the treatment
of hypertension which induces vasodilation by increasing NO
production.
Nebivolol has a distinctive profile among β-blockers, with the
greatest selectivity for cardiac β1-ARs and the highest β1-/β2-
selectivity compared with other β-blockers, and no effect on
α-receptors. Moreover, nebivolol could enhance NO release and
promote neoangiogenesis in cardiac tissue via stimulation of β3-
ARs, thus reducing heart rate and blood pressure and improving
systolic and diastolic function (Toblli et al., 2012).
Many studies underlined the importance of NO in the vasore-
laxationmechanism of nebivolol in humans suggesting the occur-
rence of an additional vascular protection in hypertension. For
instance, Cockcroft et al. investigated the effects of nebivolol
on human forearm and demonstrated that the drug induced a
potent vasodilation hampered by NO inhibitors, such as L-NAME
(Cockcroft et al., 1995). Moreover, by comparing the effects of
nebivolol and atenolol, another β1-antagonist, on the endothe-
lial function of hypertensive patients, Tzemos et al. showed that
nebivolol, differently from atenolol, was able to lower blood
pressure with a concomitant reversing action on endothelial
dysfunction (Tzemos et al., 2001).
The mechanism by which nebivolol acts on NO bioactivity is
still unclear, but it is conceivable that the drug increases intracel-
lular free calcium concentration by activating phospholipase C.
Studies suggested that the NO-mediated vascular effects of
nebivolol may be explained considering a pharmacological cross-
reactivity between serotonin 5-HT1 receptor and β-ARs (Fargin
et al., 1998).
In addition, nebivolol exerts systemic antioxidative proper-
ties and this effect was hypothesized as an additional factor
for increasing NO bioavailability. For example, nebivolol and
atenolol similarly reduced blood pressure values in hypertensive
patients, but oxidative stress markers, such as LDL hydroper-
oxides, 8-isoprostanes, ox-LDL were significantly improved
only in patients treated with nebivolol (Troost et al., 2000;
Fratta Pasini et al., 2005; Wojciechowski and Papademetriou,
2008).
The antioxidative property of nebivolol concurs to consider
it as an optimal therapeutic presidium. In fact it was demon-
strated that permanent β-ARs stimulation, typically observed
during CVD, could induce an over-expression and an activation
of eNOS which in turn lead to oxidative stress through superoxide
anion generation and a paradoxically consequent decrease of NO
bioavailability (Davel et al., 2006).
HF is another disease in which the NO pathway is recognized
to have a crucial role. It is a very complex pathology characterized
by cardiovascular dysfunction and also by diminished vascular
NO bioavailability (Recchia et al., 1998; Sun et al., 2000; Wiemer
et al., 2001; Rengo et al., 2012c).
By using down and up-regulation of all types of human NOS
genes in genetically modified mice, the involvement of NO in
the pathogenesis of HF has been largely investigated and many
experimental studies have demonstrated that eNOS isoform plays
a protective role in HF.
For example, Janssens et al. showed that overexpression of
eNOS enzyme preserves cardiac function and limits cardiac
remodeling in transgenic mice over expressing human eNOS
enzyme (Janssens et al., 2004).
Moreover, Jones et al. demonstrated that mice over expressing
eNOS displayed reduction in pulmonary edema and increase in
survival without differences in ventricular morphology and func-
tion, proposing that eNOS-derived NO might exert its beneficial
role by decreasing vascular resistance (Jones et al., 2003).
Vice versa, eNOS deficient mice develop severe cardiac dys-
function and remodeling after myocardial infarction (MI).
Scherrer-Crosbie et al. studied the impact of eNOS in left
ventricular remodeling after MI in eNOS- KO mice, conclud-
ing that eNOS has a key role in limiting cardiac dysfunction
and remodeling, in part by decreasing myocyte hypertrophy in
the remote myocardium (Scherrer-Crosbie et al., 2001; Cannavo
et al., 2013a).
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The modulation of renin-angiotensin-aldosterone axis and
adrenergic system are key elements in the therapy of several
pathologies, including Alzheimer Disease (Femminella et al.,
2013) and CVD, such as coronary artery diseases and HF
(Marciano et al., 2012; Rengo et al., 2012b, 2013b).
It has been reported that NO is involved in beneficial effects
of drugs, including statins, Angiotensin Converting Enzyme
inhibitors (ACE-I), Angiotensin II Type 1 receptor blockers
(ARBs) and β-blockers.
Statin therapy significantly enhances NO bioavailability in
endothelial cells and exert beneficial effects in several molecular
aspects of the MI, including neovascularization, LV dysfunction,
interstitial fibrosis, remodeling and survival (Landmesser et al.,
2004).
Both ACE-I and ARBs generate cardioprotective effects inmice
with post-ischemic HF by improving left ventricular function and
attenuating fibrosis and hypertrophy (Cavasin et al., 2000). It
was demonstrated that in eNOS-KO mice with HF the beneficial
effects of these drugs were abolished, suggesting that NO is a key
regulator of the ACE-I and ARBs effects (Liu et al., 2002).
Moreover, the treatment with β-blockers improves LV systolic
function and produces positive cardiac remodeling (Colucci et al.,
2007).
In particular, recent studies demonstrated that the third
generation β-blockers possess important additional properties
besides inhibiting β-adrenoceptors. Among them, nebivolol and
carvedilol enhance the bioavailability of NO by both inducing
endothelial NO synthesis and preventing free radicals-mediated
NO inactivation. Therefore, these drugs show advantages com-
pared to the conventional β-antagonists (Vanhoutte and Gao,
2013).
Several studies indicated carvedilol, in addition to conven-
tional therapy, as the preferred β-blocker in the treatment of
chronic HF.
Packer et al. performed a double-blind, placebo-controlled
study in 1094 patients with chronic HF, demonstrating that
carvedilol considerably reduced hospitalization and mortality
rates for cardiovascular causes (Packer et al., 1996).
Moreover, combined results of studies in the US Carvedilol HF
Trials Program revealed that mortality was significantly lower in
carvedilol than in placebo recipients (Keating and Jarvis, 2003).
Nebivolol, endowed with a significant NO-associated vasodi-
lating effect, did not provide the same results. SENIORS trial on
nebivolol effects in elderly patients with HF displayed a reduc-
tion in cardiovascular mortality, but the US Food and Drug
Administration did not approve this drug for the treatment of
HF because the improvement in the systolic function of patients
treated with nebivolol was not as substantial as with other β-
blockers (Nair et al., 2012).
There is now compelling evidence that reduced NO bioavail-
ability due to sympathetic hyperactivity is the major con-
tributor to endothelial dysfunction. Thus, the effects on
endothelial dysfunction of the last generated vasodilating β-
antagonists might have important clinical implications, particu-
larly in patients with resistant hypertension and possibly in the
treatment of HF.
EXERCISE TRAINING IMPROVES NITRIC OXIDE FUNCTION
ET influences cardiovascular function and endothelial homeosta-
sis and it is recommended to treat age-associated disorders and
CVD (Leosco et al., 2008; Rengo et al., 2010; Conti et al., 2012b).
ET improves the efficiency of the endogenous antioxidant sys-
tem and reduces cellular oxidation rate through the stimulation of
several molecular pathways (Rinaldi et al., 2006). Oxidants, and
ROS, more particularly, play an important role in several physio-
logical processes, but their overproduction is responsible for the
generation of oxidative stress, that may in turn directly or indi-
rectly damage cellular constituents, including DNA, proteins, and
lipids (Ferrara et al., 2008; Conti et al., 2013).
It has been demonstrated that ET contributes to maintain the
balance between ROS and antioxidant activity (Corbi et al., 2012),
thus preventing oxidative stress, which is present in all stages of
both vascular and non-vascular diseases (Carrizzo et al., 2013a;
Puca et al., 2013).
One of the main beneficial effects of ET on the cardiovascu-
lar system is related to its ability to enhance NO production and
release.
Yang et al. demonstrated that ET induces an increase of
blood flow in collateral vessels of ischemic muscles and that
NO inhibition abolished this effect. The authors suggested that
one of the vascular adaptations induced by ET is an increase
of the NO-mediated actions, which eventually culminate in the
improvement of the endothelial function (Yang et al., 2008).
The endothelial function, strongly influenced by NO, may
improve after exercise both in animal models and in humans; sev-
eral studies in both healthy subjects and patients with impaired
NO-related vasorelaxation remarked ET ability to improve vas-
cular structure and function and endothelial homeostasis (Green
et al., 2004).
Endothelial dysfunction play a fundamental role both in
the onset and progression of CVD and it has been suggested
that decreased NO bioavailability could definitely favors the
proatherogenic endothelial cell phenotype.
Numerous studies have underlined a fundamental role played
by endothelial dysfunction in both onset and progression of CVD
and it has been suggested that decreased NO bioavailability could
definitely favors the proatherogenic endothelial cell phenotype
(Stary et al., 1994; Libby et al., 2002; Taimeh et al., 2013). CVD
progression can be slowed, stopped, or even reversed by life-style
interventions, including regular physical activity and these effects
are often associated with an increase in NO bioavailability and
NO metabolites (Rush et al., 2005; Carrizzo et al., 2013b).
Exercise-based CR is now considered a valid therapeutic
approach against CVD since it reduces morbidity and mortal-
ity. Exercise benefit depends almost in part on the exercise-based
increase of NO generation, which in turn improves the endothe-
lial function (Linke et al., 2008).
Laurent et al. investigated the effects of water-based exercises
in patients with stable chronic HF or coronary artery disease,
and found that this type of CR was effective in increasing the
basal level of plasma nitrates. Such modification may be related
to an improvement of the endothelial function and may be of
significance for patients’ health (Laurent et al., 2009).
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In recent years evidences about the relationship among ET,
adrenergic system and NO, have been accumulating. Calvert
et al. clearly demonstrated that exercise protects the heart
by stimulating β3-ARs and increasing cardiac storage of NO
metabolites. The authors observed an increase of NO genera-
tion and of cardiac nitrite and nitrosothiol levels in exercised
mice. In addition, they remarked a critical role played by β3-
ARs in regulating the phosphorylation (activation) of eNOS and
the generation of NO in response to exercise (Calvert et al.,
2011).
Due to its short half-life, it is very difficult to assess
NO endothelial production in humans and all NO bioassays,
albeit undoubtedly representing a practical surrogate to mea-
sure endothelial function in vivo, show some relevant limitations
(Green et al., 2004).
As a consequence, novel strategies to unravel the molecular
mechanisms influenced by NO are required. In this context, ET
could be for example considered as a practical indirect approach
to study NO effects in the endothelial cells (Conti et al., 2013).
NITRIC OXIDE SYNTASES AND ADRENORECEPTORS
GENETIC VARIABILITY
Extensive evidence has been recently accumulated that polymor-
phisms in genes encoding for ARs and NO synthase enzymes
might influence aging, onset and progression of CVD and therapy
response.
Montesanto et al., for instance, investigated the genetic
variability linked to the three enzymatic isoforms of NO synthase
(nNOS, iNOS and eNOS), and observed that genetic variants
of NOS genes influenced both aging phenotypes and longevity
in humans. The Authors verified the presence of a correlation
between nNOS and iNOS polymorphisms and longevity from
one side, and between nNOS and eNOS variants with the
presence, respectively, of depression symptoms and disability
from the other (Montesanto et al., 2013).
In addition, increasing evidence suggests that genetic
polymorphisms are responsible for different cardiovascu-
lar outcomes following the use of antihypertensive drugs.
Jáchymová et al. analysed the common polymorphism
FIGURE 1 | NO is involved in the sympathetic regulation of vascular tone
and in the control of endothelium homeostasis. The main mechanism
leading to increased eNOS activity in endothelial cells is calcium-dependent,
but phosphorylation at several loci of the NOS proteins has been recognized
as an additional pathway to induce both activation and inhibition of eNOS
activity. NO diffuses to vascular smooth muscle and produces relaxation by
stimulating sGC to increase the levels of the second messenger cGMP.
Vascular endothelial cells might also express β-adrenoceptors, thus
supporting the hypothesis that the endothelium might control or facilitate
β-adrenergic effects on the vessels. Acute β-adrenergic activation caused by
β-adrenoceptor agonists stimulates eNOS activity and could increase release
of endothelial NO. Permanently high catecholamine levels could lead to
overactivation of β-adrenoceptors, increasing eNOS activity and expression.
This condition may lead to the uncoupling of eNOS, which produces O2− and
ONOO− (ROS). An unbalanced production of NO and O2− is responsible for
the formation of ONOO−, thus provoking vascular dysfunction. Several
stimuli, such as oscillatory shear stress, hyperglycemia and lipid peroxidation
could cause impairment in the NADPH oxidase system that, in turn, produces
accumulation of ROS and reduction of NO content. Nebivolol, a β-blocker
with a distinctive profile, combines the properties of a β1-AR antagonist and
β3-AR agonist. Nebivolol could enhance NO release via stimulation of β3-ARs
and, thanks to its antioxidant activity, it prevents the detrimental effect on NO
bioavailability associated to oxidative stress. Life-style changes and
non-pharmacological interventions (such as caloric restriction and exercise
training) show a positive role on the maintenance of cardiovascular
homeostasis, at least in part, by inducing the activation of eNOS and
increasing NO bioavailability. Abbreviations: AR, adrenoreceptor; cGMP, cyclic
guanosine monophosphate; eNOS, endothelial nitric oxide synthase; GTP,
guanosine 5′-triphosphate; NADPH, reduced nicotinamide adenine
dinucleotide phosphate; NO, nitric oxide; O−2 , superoxide; ONOO
−,
peroxynitrite; P, phosphoryl; ROS, reactive oxygen species; sGC, soluble
guanylate cyclase. ↓ Activation; ⊥ inhibition.
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Glu298Asp, located in the eNOS gene, in a group of patients
with hypertension and in age-matched healthy subjects.
They found that this polymorphism was associated with an
insufficient response of patients to conventional therapy,
thus suggesting that this genetic variant may concur to the
pathogenesis of essential hypertension (Jáchymová et al.,
2001).
Zhang et al. studied several eNOS polymorphisms, highlight-
ing a significative correlation between the presence of these vari-
ants, coronary heart diseases (CHD) and HF. In particular, this
study showed that patients bearing minor allele of −690 C > T
polymorphism had higher risk in CHD and minor allele carriers
for −922 A> G variant had higher risk in HF.
Moreover, a genotype-dependent variability in the therapy
response of patients randomized to the amlodipine or to the
lisinopril and clorthalidone treatments was described (Zhang
et al., 2012). Indeed, minor allele carriers treated with amlodip-
ine showed better outcomes, when compared exclusively to those
treated with lisinopril, including changes in systolic and diastolic
blood pressure. These pharmacogenetic data suggested that eNOS
genotyping might be useful to select the most effective and safe
treatment to obtain the best individual therapy response.
Previous studies have suggested that eNOS Glu298Asp poly-
morphism could influence NO synthesis through the expression
of a protein with different susceptibility to cleavage (Tesauro et al.,
2000) and the same variant has been correlated with endothe-
lial function (Savvidou et al., 2001; Leeson et al., 2002). These
results, together with other epidemiological data, suggested that
eNOS polymorphisms, other than the Glu298Asp, could play a
role in influencing the onset and progression of vascular diseases,
including CHD, HF and hypertension (Benjafield and Morris,
2000).
Besides the pharmacogenetic effect linked to conventional
drug therapies, it was showed that Glu298Asp eNOS gene poly-
morphismmight interact with environmental and dietary factors,
such as smoking and n-3 fatty acid, influencing endothelial func-
tion (Leeson et al., 2002).
In addition, also ET-associated antihypertensive effects have
been reported to vary on the basis of the individual genetic back-
ground. It is worth to note that a polymorphism (−786 T > C)
in the promoter region of the eNOS gene was indicated as an
influencing factor of exercise beneficial effects (Augeri et al.,
2009).
Some studies suggested that changes in NO synthesis con-
tribute to a vasodilator response variability to β2 agonists. It was
observed that forearm blood flow response to isoproterenol is
impaired in men with hypercholesterolemia, a condition associ-
ated with dysfunctional NO activity (Chowienczyk et al., 1992).
Moreover, the β-adrenergic vasorelaxation in the human fore-
arm is reduced by N-monomethyl-l-arginine (L-NMMA), an
inhibitor of nitric oxide synthase, confirming the crucial role
played by NO in the sympathetic regulation of vascular tone
(Dawes et al., 1997).
Several polymorphisms located in the gene encoding β2-
receptors have been correlated to the difference in the expres-
sion, coupling and agonist regulation of these receptors.
Polymorphisms affecting amino acids 16, 27, and 164 are the
most common genetic variants and, for example, the Arg16Gly
is known to predispose to agonist-induced down-regulation and
desensitization of the receptors, probably concurring to the
pathogenesis of asthma severity (Green et al., 1993; Reihsaus et al.,
1993).
To confirm the involvement of the NO pathway in the β2-
adrenoreceptor-dependent vasodilation control, Garovic et al.
showed that the forearm blood flow response to isoproterenol was
greater in Gly 16 then in Arg 16 homozygotes and that response
was inhibited by L-NMMA (Garovic et al., 2003).
To date, many authors reported that adrenoreceptor (in
particular, β2-receptors) polymorphisms are strongly associated
to cardiovascular outcomes, including blood pressure, and to pre-
disposition (Timmermann et al., 1998; Bray et al., 2000) and
treatment (Johnson and Terra, 2002; McNamara et al., 2002;
Taylor and Bristow, 2004) of CVD.
The studies described above confirm that analysis of patients
DNA may be useful to understand sympathetic vasodilation
mechanism and implication of NO pathway and to create new
therapeutical strategies against CVD.
CONCLUSIONS
The maintenance of myocardial and vascular homeostasis is one
of the many diverse physiological functions mediated by NO, a
versatile and nearly ubiquitous molecule that plays a key function
as a signaling molecule throughout the body. An imbalance in
either the production or release of this molecule is correlated to
CVD such as hypertension and HF.
It is now evident that the control of endothelium homeostasis
and the sympathetic regulation of the vascular tone are the result
of a complex crosstalk between NO, β-adrenoreceptors (in par-
ticular the β3 subtype) and oxidative stress. As an example, recent
advances on the β1-selective antagonist nebivolol remarked the
importance of NO bioavailability in the maintenance of myocar-
dial and vascular homeostasis. A scheme representing some of the
functions in which the pathway of NO is strongly involved was
presented in Figure 1.
It is our opinion that the effective clinical/therapeutic man-
agement of CVD requires the understanding of the molecular
determinants responsible for this crosstalk to identify new targets
and develop new clinical strategies.
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